Conor Announces Positive Angiographic Results for EuroSTAR

Conor Medsystems presented angiographic and clinical data from the company's pivotal EuroSTAR study evaluating its CoStar cobalt chromium paclitaxel-eluting stent in a complex patient cohort.

The six-month follow-up data, demonstrating positive angiographic and clinical results for the treatment of single or multiple de novo lesions in native coronary arteries, were presented at the DES Revolution IV, a Cardiovascular Research Foundation-sponsored symposium immediately preceding the American College of Cardiology meeting in Orlando, Fla.

A total of 176 lesions were treated in 145 patients using the CoStar stent formulated to release a therapeutic dose of 10 mcg of paclitaxel over approximately 30 days (based on in vitro measurements). At six-month follow-up, the in-stent binary restenosis rate was 3.4 percent and the in-stent late loss was 0.26 mm. The in-segment binary restenosis rate was 4.7 percent and the in-segment late loss was 0.07 mm. As previously reported, the target lesion revascularization rate was 1.7 percent and the rate of cumulative major adverse cardiac events was 4.8 percent.